Core Insights - Aptevo Therapeutics has entered into a $60 million equity line of credit (ELOC) agreement with Yorkville Advisors Global, LP, enhancing its financial flexibility and extending its funding runway into 2029 [1][2][3] Financial Flexibility - The ELOC allows Aptevo to raise funds incrementally at its discretion under market-based conditions, providing affordable capital financing with minimal fees and no warrants [2][3] - The combination of the ELOC and cash on hand is projected to fund the company for three years, allowing for the achievement of key clinical and preclinical milestones [1][3] Clinical Development - Aptevo's portfolio includes five CD3-engaging assets, with mipletamig being a first-in-class CD123 x CD3 bispecific currently evaluated in a Phase 1b/2 trial for frontline acute myeloid leukemia (AML) [5][7] - Mipletamig has shown high remission rates and a favorable safety profile in over 100 patients across three trials, with no observed cytokine release syndrome events [5][6] Pipeline and Innovation - The company is advancing a portfolio of tumor-directed CD3 programs, including bispecific candidates for prostate cancer and solid tumors, utilizing proprietary CRIS-7-derived CD3 binding domains [6][7] - Aptevo has two clinical candidates and six preclinical candidates targeting various solid tumors, all developed from its ADAPTIR and ADAPTIR-FLEX platforms [7]

Core Viewpoint - Tactical Resources Corp has secured a significant financing agreement to support its business combination and enhance its position in the rare earth elements market [1] Financing Agreement - The financing agreement with Yorkville Advisors Global includes up to US$40 million in convertible debt financing and a US$100 million standby equity purchase agreement [1] - This comprehensive financing package is aimed at facilitating the business combination with Plum Acquisition Corp. III [1] Strategic Positioning - The combined company, referred to as PubCo, is expected to list publicly on Nasdaq [1] - The financing will also aid in accelerating near-term project development and the potential commercial supply of domestic rare earth elements [1]

Core Insights - Rein Therapeutics has entered into two strategic financing agreements with Yorkville Advisors Global, LP, potentially providing access to up to $21 million in capital to support its clinical trials and pipeline advancement [1][2]. Financing Details - The financing consists of a $6 million pre-paid advance agreement, with an initial $1 million advance funded at signing, and a $15 million standby equity purchase agreement (SEPA) that can be utilized at the company's discretion over 36 months [9]. - The pre-paid advance facility allows for up to $6 million to be drawn in mutually agreed tranches over the next twelve months, with each advance purchased at a 5% discount and repayable in common stock if requested by Yorkville [9]. - The SEPA gives Rein the option to sell up to $15 million of common stock over 36 months, contingent upon an effective registration statement [9]. Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [7]. - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in clinical development for idiopathic pulmonary fibrosis (IPF) [7]. - Rein's second product candidate, LTI-01, has completed Phase 1b and Phase 2a clinical trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. [7].

Core Viewpoint - NOVONIX Limited has entered into a definitive Funding Agreement to secure up to US$95,000,000 for the expansion of its Riverside facility in Chattanooga, Tennessee, through the issuance of unsecured convertible debentures [1][9]. Funding Agreement Details - The Funding Agreement allows NOVONIX to issue up to US$100,000,000 in convertible debentures to Yorkville Advisors Global, LP [1][9]. - The first tranche consists of US$24,500,000, which will raise US$23,275,000 and does not require shareholder approval [9]. - The second tranche is US$35,500,000, which may raise up to an additional US$33,725,000, subject to shareholder approval at an Extraordinary General Meeting scheduled for September 9, 2025 [9]. - An additional tranche of up to US$40,000,000 is also available, contingent on mutual agreement and shareholder approval [9]. Production and Capacity Expansion - NOVONIX plans to begin shipping commercial-grade synthetic graphite from its Riverside facility later this year, with mass production set to start next year for its lead customer, Panasonic [2]. - The Riverside facility is expected to become the first large-scale production site for high-performance synthetic graphite in North America, with an initial capacity scaling up to 20,000 tonnes per annum (tpa) [5]. - Combined with the new Enterprise South location, NOVONIX will achieve a total production capacity of over 50,000 tpa in Chattanooga [5]. Company Overview - NOVONIX is recognized as a leading battery technology company focused on revolutionizing the lithium-ion battery industry through innovative and sustainable technologies [7]. - The company is expanding its high-performance synthetic graphite material manufacturing operations and has developed a patented all-dry, zero-waste cathode synthesis process [7].

Core Insights - Predictive Oncology Inc. has entered into a standby equity purchase agreement (SEPA) with YA II PN, LTD, managed by Yorkville Advisors Global, LP, to secure funding for its drug discovery initiatives [1][2] - The SEPA allows Predictive Oncology to sell up to $10 million worth of its stock at its discretion, with no minimum commitments or penalties for non-use [2] - The company leverages its AI-driven platform, PEDAL, which predicts drug response with 92% accuracy, enhancing drug discovery for cancer treatment [4] Funding Agreement - The SEPA provides Predictive Oncology with a flexible funding source to support ongoing drug discovery, biomarker discovery, and drug repurposing efforts [1] - Yorkville is obligated to purchase the stock, but Predictive Oncology controls the timing and amount of sales [2] - There are no associated warrants, derivatives, or other share classes with the SEPA, and it does not restrict the company's operational activities [2] Company Overview - Predictive Oncology specializes in AI and machine learning applications in drug discovery, aiming to expedite the development of cancer treatments [4] - The company has a biobank of over 150,000 tumor samples, enhancing its drug discovery capabilities [4] - Predictive Oncology is headquartered in Pittsburgh, PA, and offers one of the industry's broadest AI-based drug discovery solutions [4]

As filed with the U.S. Securities and Exchange Commission on June 6, 2025 Registration No. 333-286569 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ___________________________________ Yorkville Acquisition Corp. (Exact name of registrant as specified in its charter) ___________________________________ | | | (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial C ...

Core Viewpoint - Scinai Immunotherapeutics Ltd. has entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to sell up to $10 million of its American Depository Shares (ADSs) over a three-year period to support its R&D and CDMO business expansion [1][2][5]. Group 1: SEPA Details - The SEPA allows Scinai to sell ADSs at a 3% discount to the lowest daily volume-weighted average price over three consecutive trading days following an advance notice [3]. - Scinai retains full control over the timing and amount of sales under the SEPA, with no obligation to utilize the full $10 million [4]. - The agreement includes a beneficial ownership cap of 9.99% of Scinai's share capital at any one time, along with other restrictions [2]. Group 2: Use of Proceeds - Proceeds from the potential offering of ADSs under the SEPA will be used to further develop NanoAbs programs, support the CDMO business, and for general corporate purposes including working capital and regulatory matters [5]. Group 3: Company Overview - Scinai Immunotherapeutics is focused on developing inflammation and immunology biological products and offers CDMO services through its Scinai Bioservices unit [1][7]. - The company has a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with significant unmet medical needs [7].

Table of Contents As filed with the U.S. Securities and Exchange Commission on May 17, 2024. Registration No. 333-278460 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QT Imaging Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 6770 85-1728920 (Primary Standard Industrial Classification Code No.) (I.R.S. Empl ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on April 24, 2024. Registration No. 333-278460 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 QT Imaging Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 6770 85-1728920 (Primary Standard Industrial Classification Code No.) (I.R.S. Em ...